A novel artificial endothelial replacement membrane for the treatment of chronic corneal edema
Purpose: The purpose of this study was to report the safety and efficacy results of an artificial lamellar implant for the treatment of chronic corneal edema. Methods: The EndoArt (EyeYon Medical, Ness Ziona, Israel), an artificial endothelial replacement membrane designed to treat corneal edema, wa...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
October 2025
|
| In: |
Cornea
Year: 2025, Volume: 44, Issue: 10, Pages: 1240-1247 |
| ISSN: | 1536-4798 |
| DOI: | 10.1097/ICO.0000000000003734 |
| Online Access: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1097/ICO.0000000000003734 Verlag, kostenfrei, Volltext: https://journals.lww.com/corneajrnl/fulltext/2025/10000/a_novel_artificial_endothelial_replacement.5.aspx 
|
| Author Notes: | Ofer Daphna, Gerd U. Auffarth, Ruth Lapid-Gortzak, Sunita Chaurasia, Efrat Gilboa, Anat Lemze, Michael Dover, and Arie L. Marcovich |
| Summary: | Purpose: The purpose of this study was to report the safety and efficacy results of an artificial lamellar implant for the treatment of chronic corneal edema. Methods: The EndoArt (EyeYon Medical, Ness Ziona, Israel), an artificial endothelial replacement membrane designed to treat corneal edema, was implanted in 24 eyes of 24 patients with low-to-normal visual potential. We present the safety and efficacy results from a prospective, open-label, single-arm, multicenter study conducted over a 12-month period. Results: Twenty-four patients were enrolled, with no device-related serious adverse events reported. Seventeen patients completed 12-month follow-up, showing a reduction in average central corneal thickness from 759 ± 116 μm to 613 ± 135 μm. Best-corrected distance visual acuity improved from 1.88 ± 0.79 logarithmic minimum angle of resolution (logMAR) to 1.34 ± 0.57 logMAR. Sixty percent gained at least 3 early treatment diabetic retinopathy study (ETDRS) lines. The EndoArt was removed in 5 cases due to incomplete attachment and replaced by corneal transplants; 1 patient was lost to follow-up, and 1 had a procedure failure. No device-related long-term complications, infections, or inflammations were reported. The implants remained transparent throughout the study. Conclusions: The first-in-human results of EndoArt implantation demonstrated the device's potential to treat patients suffering from corneal edema with a favorable safety profile and effective edema reduction in most subjects, with no device-related serious adverse event. The EndoArt may offer a viable solution in regions facing a shortage of donor corneas, as well as for patients who have poor prognosis with human tissue. |
|---|---|
| Item Description: | Gesehen am 17.06.2026 |
| Physical Description: | Online Resource |
| ISSN: | 1536-4798 |
| DOI: | 10.1097/ICO.0000000000003734 |